CCL5 and pancreatic neoplasm: Furthermore, we noted increased sizes of subcutaneous tumors after intratumoral injection of CCL5 or serpin E1, which was particularly evident in the pCDH-shSRI groups (Fig. 5l, m), indicating the potential collaborative effects of SRI and downstream inflammatory cytokines on the proliferation of pancreatic cancer cells.